Compare MARKSANS PHARMA. with ANUH PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MARKSANS PHARMA. vs ANUH PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MARKSANS PHARMA. ANUH PHARMA MARKSANS PHARMA./
ANUH PHARMA
 
P/E (TTM) x 9.4 26.6 35.2% View Chart
P/BV x 2.6 2.7 97.1% View Chart
Dividend Yield % 0.4 1.5 30.1%  

Financials

 MARKSANS PHARMA.   ANUH PHARMA
EQUITY SHARE DATA
    MARKSANS PHARMA.
Mar-21
ANUH PHARMA
Mar-21
MARKSANS PHARMA./
ANUH PHARMA
5-Yr Chart
Click to enlarge
High Rs66219 30.2%   
Low Rs1354 24.2%   
Sales per share (Unadj.) Rs33.686.2 39.0%  
Earnings per share (Unadj.) Rs5.85.7 102.7%  
Cash flow per share (Unadj.) Rs6.78.7 77.3%  
Dividends per share (Unadj.) Rs0.251.50 16.7%  
Avg Dividend yield %0.61.1 57.4%  
Book value per share (Unadj.) Rs21.738.0 56.9%  
Shares outstanding (eoy) m409.3150.11 816.8%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x1.21.6 74.4%   
Avg P/E ratio x6.824.0 28.3%  
P/CF ratio (eoy) x5.915.7 37.6%  
Price / Book Value ratio x1.83.6 51.0%  
Dividend payout %4.326.4 16.2%   
Avg Mkt Cap Rs m16,1886,826 237.2%   
No. of employees `000NANA-   
Total wages/salary Rs m1,973143 1,380.8%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m13,7624,320 318.6%  
Other income Rs m67105 63.5%   
Total revenues Rs m13,8294,425 312.5%   
Gross profit Rs m3,396451 752.7%  
Depreciation Rs m362151 239.8%   
Interest Rs m8020 393.4%   
Profit before tax Rs m3,022386 783.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m636101 629.0%   
Profit after tax Rs m2,385284 838.9%  
Gross profit margin %24.710.4 236.3%  
Effective tax rate %21.126.2 80.3%   
Net profit margin %17.36.6 263.3%  
BALANCE SHEET DATA
Current assets Rs m9,0232,377 379.5%   
Current liabilities Rs m2,9841,395 214.0%   
Net working cap to sales %43.922.7 192.9%  
Current ratio x3.01.7 177.4%  
Inventory Days Days129 3.8%  
Debtors Days Days71,977,516903 7,971,299.0%  
Net fixed assets Rs m3,252949 342.6%   
Share capital Rs m409251 163.4%   
"Free" reserves Rs m8,4561,656 510.6%   
Net worth Rs m8,8651,906 465.0%   
Long term debt Rs m00-   
Total assets Rs m12,2753,326 369.0%  
Interest coverage x38.820.0 194.3%   
Debt to equity ratio x00-  
Sales to assets ratio x1.11.3 86.3%   
Return on assets %20.19.2 219.3%  
Return on equity %26.914.9 180.4%  
Return on capital %35.021.3 164.4%  
Exports to sales %049.2 0.0%   
Imports to sales %7.467.8 10.9%   
Exports (fob) Rs mNA2,125 0.0%   
Imports (cif) Rs m1,0142,927 34.6%   
Fx inflow Rs m5,8742,125 276.4%   
Fx outflow Rs m1,0142,927 34.6%   
Net fx Rs m4,860-802 -605.8%   
CASH FLOW
From Operations Rs m1,787-187 -954.0%  
From Investments Rs m-449522 -86.0%  
From Financial Activity Rs m-153-331 46.2%  
Net Cashflow Rs m1,1864 33,586.1%  

Share Holding

Indian Promoters % 48.3 70.4 68.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.2 0.0 -  
FIIs % 2.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 51.8 29.6 175.0%  
Shareholders   201,451 22,779 884.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MARKSANS PHARMA. With:   ADESHWAR MEDITEX  UNICK FIX-A-FORM AND PRINTERS  PHAARMASIA  AURO LAB.  TTK HEALTHCARE  



Today's Market

Sensex Falls 1,100 Points from Day's High to End Marginally Lower; Metal & Energy Stocks Witness Selling(Closing)

It was indeed a volatile trading session for Indian share markets today. Benchmark indices reversed course in intraday deals as global cues turned bearish.

Related Views on News

MARKSANS PHARMA. 2020-21 Annual Report Analysis (Annual Result Update)

Nov 9, 2021 | Updated on Nov 9, 2021

Here's an analysis of the annual report of MARKSANS PHARMA. for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of MARKSANS PHARMA.. Also includes updates on the valuation of MARKSANS PHARMA..

ANUH PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Oct 27, 2021 | Updated on Oct 27, 2021

Here's an analysis of the annual report of ANUH PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of ANUH PHARMA. Also includes updates on the valuation of ANUH PHARMA.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

More Views on News

Most Popular

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake(Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

Don't Sell these Stocks if the Market Falls(Profit Hunter)

Nov 17, 2021

These are the 3 types of stocks that you should not sell in a market crash.

How to Find Your Next 10-Bagger in this Market(Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

6 Popular Stocks that Turned into Penny Stocks(Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MARKSANS PHARMA. SHARE PRICE


Nov 30, 2021 (Close)

TRACK MARKSANS PHARMA.

  • Track your investment in MARKSANS PHARMA. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON MARKSANS PHARMA.

MARKSANS PHARMA. 5-YR ANALYSIS

COMPARE MARKSANS PHARMA. WITH

MARKET STATS